Vaccine developer Aeras and CMO (contract manufacturing organization) IDT Biologika have formed a strategic partnership that includes the acquisition of Aeras's Biopharmaceutical Development Center (BDC) manufacturing facility by IDT.
Scientists have developed a new way of visualizing multiple myelomas in 3D by replicating tumours in hens’ eggs in a approach they say will aid drugmakers.
Mice engineered to recognise light-emitting markers as self will let cancer drug developers to track tumor growth in animals with functioning immune systems say US researchers.
Aragen Bioscience and Transposagen Biopharmaceuticals have launched a knockout CHO cell line and development services they clam allows for the development of more effective therapeutic mAbs.
Rumoured Big Pharma takeover target GSK has invested $95m to set up an cell genetics research institute to help developers better identify drug candidates.
Correctly identifying cell lines used in cancer drug development would cut the amount US researchers spend on preclinical research that cannot be reproduced.
California-based Allele has bought a facility to manufacture human induced pluripotent stem cells (hiPSCs) using its “footprint-free” synthetic mRNA technology.
Aspyrian Therapeutics has selected CDMO Goodwin Biotechnology to complete process development, scale-up, and cGMP manufacturing of their novel antibody drug conjugate (ADC).
Unchained Labs has acquired Avia Biosystems and its characterization tool, the Isothermal Chemical Denaturation (ICD) system, to support the growing demand for biologics stability testing.
Takeda is closing three US R&D facilities and relocating its global HQ to a site in Massachusetts as part of plans to consolidate its vaccine business.
Intertek will open an immunochemistry lab in Manchester, UK to cater for growing demand for specialised analytical services from biologics and biosimilars developers.
The adoption of new technologies related to single-use bioreactors, disposable plastic containers, continuous purification processing, and real-time quality analysis are driving the next generation of biomanufacturing, according to a new report from the...
Innovate UK has awarded Crescendo Biologics a grant to fund development of drugs combining cytotoxic small molecule payloads with antibody fragments known as Humabodies.
Dutch scientists have 3D printed a protective scaffold that could make cell transplant-based diabetes treatment more successful and eliminate the need for immunosupressive drugs.
Novartis has partnered with Google-backed Rani Therapeutics to assess an oral platform which delivers biologics through the intestinal wall using needles made of sugar.
As the largest pharma and tech suppliers – from Novartis to GE Healthcare to Thermo Fisher – begin exploring the world of CRISPR/Cas gene editing technology, contract research organizations are also looking into the new tech to explore ways to help clients’...
Big Pharma is not the only slow moving behemoth involved in the CRISPR/Cas9 revolution with a US team citing the gene editing tech as key to its efforts to resurrect the woolly mammoth.
Medicago has ploughed $245m into an influenza vaccine plant that will use a tobacco-based technology it says produces high yields quicker than with egg-based platforms.
Pfizer has invested $87.5m in Dutch biopharma AM-Pharma B.V., which develops recombinant human Alkaline Phosphatase (recAP) therapies for orphan inflammatory diseases.
A new study is shaking up ideas about a known therapeutic strategy for Alzheimer’s disease, following a discovery by scientists at Scripps Research Institute testing enzyme inhibitors.
Oncobiologics, a biotherapeutics company focused on developing and commercializing monoclonal antibody (mAb) biosimilars, has completed the construction of its GMP commercial manufacturing facility at its headquarters in Cranbury, New Jersey.
Most Brits would want to know if they carry genes linked to life-threatening diseases according to UK researchers who say this could have implications for drug development.
Merck & Co. will invest €11.5m ($12.5m) at a plant in Ireland to manufacture its oncology drug Keytruda, an anti-PD1 mAb recently approved by the US FDA.
US researchers have discovered the most precise method yet for measuring the structure of monoclonal antibodies. The technique gives manufacturers and regulators a way of assessing and comparing the performance and quality of mAbs using nuclear magnetic...
Medgenics has expanded a partnership with Harvard University to use its Transduced Autologous Regenerative Gene Therapy (TARGT) platform for potential applications involving the central nervous system.
Ireland is trying to compete in biomanufacturing with powerhouses like Puerto Rico and Singapore thanks to government-financed innovation in process development.
Almac will transfer its custom peptide manufacturing business to a site at the Edinburgh Technopole business park in Scotland’s capital in a £3.5m move designed to expand capacity.
An Ebola viral vector vaccine in development by Profectus BioSciences works in monkeys against the virus strain currently infecting humans in West Africa.
Pfizer’s termination of a partnership to develop Factor VIIa products may have implications in the recently announced merger of Catalyst Biosciences with Targacept.
Bristol-Myers Squibb will use uniQure’s insect-cell based technology and manufacturing facilities to develop gene therapies for cardiovascular diseases in a deal potentially worth $2bn (€1.8bn).
Fujifilm will buy Cellular Dynamics International (CDI) for $307m to add induced stem cells to its offering and further build in regenerative medicines.
British MPs have signed an anti-animal cruelty pledge which scientists warn would “cripple” disease research and outlaw 89% of preclinical animal research.
